Janindra Warusavitarne1, Margaret Schnitzler. 1. Department of Cancer Genetics, Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, St. Leonards, NSW, 2065, Australia. janindra@bigpond.com
Abstract
INTRODUCTION: High-frequency microsatellite instability (MSI-H) is an alternate pathway of colorectal carcinogenesis, which accounts for 15% of all sporadic colorectal cancers. These tumours arise from mutations in the DNA mismatch repair system and thus have different responses to chemotherapeutic agents compared to microsatellite stable (MSS) cancers. OBJECTIVE: This review aims to summarise the available literature on the responses to chemotherapy in MSI-H colorectal cancer (CRC). RESULTS AND DISCUSSION: 5 Fluorouracil (5FU) is commonly used as a chemotherapeutic agent in colon cancer and in vitro evidence shows reduced response to 5FU in MSI-H CRC. The clinical evidence is conflicting but favours a reduced response to 5FU in MSI-H CRC. Several newer agents such as COX-2 inhibitors and irinotecan are also reviewed. CONCLUSION: Available evidence suggests that MSI-H CRC have different behaviour patterns and response to chemotherapy compared with MSS CRC.
INTRODUCTION: High-frequency microsatellite instability (MSI-H) is an alternate pathway of colorectal carcinogenesis, which accounts for 15% of all sporadic colorectal cancers. These tumours arise from mutations in the DNA mismatch repair system and thus have different responses to chemotherapeutic agents compared to microsatellite stable (MSS) cancers. OBJECTIVE: This review aims to summarise the available literature on the responses to chemotherapy in MSI-H colorectal cancer (CRC). RESULTS AND DISCUSSION: 5 Fluorouracil (5FU) is commonly used as a chemotherapeutic agent in colon cancer and in vitro evidence shows reduced response to 5FU in MSI-H CRC. The clinical evidence is conflicting but favours a reduced response to 5FU in MSI-H CRC. Several newer agents such as COX-2 inhibitors and irinotecan are also reviewed. CONCLUSION: Available evidence suggests that MSI-H CRC have different behaviour patterns and response to chemotherapy compared with MSS CRC.
Authors: B van Triest; H M Pinedo; J L Blaauwgeers; P J van Diest; P S Schoenmakers; D A Voorn; K Smid; K Hoekman; H F Hoitsma; G J Peters Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531
Authors: J L Masferrer; K M Leahy; A T Koki; B S Zweifel; S L Settle; B M Woerner; D A Edwards; A G Flickinger; R J Moore; K Seibert Journal: Cancer Res Date: 2000-03-01 Impact factor: 12.701
Authors: S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein Journal: Science Date: 1995-06-02 Impact factor: 47.728
Authors: Katherine M Sheehan; Fionnuala O'Connell; Anthony O'Grady; Ronan M Conroy; Mary B Leader; Michael F Byrne; Frank E Murray; Elaine W Kay Journal: Eur J Gastroenterol Hepatol Date: 2004-06 Impact factor: 2.566
Authors: Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad Journal: Int J Cancer Date: 2013-08-24 Impact factor: 7.396
Authors: Ralph H Hruban; Anirban Maitra; Richard Schulick; Daniel Laheru; Joseph Herman; Scott E Kern; Michael Goggins Journal: Gastrointest Cancer Res Date: 2008-07
Authors: Alexandros D Polydorides; Bhramar Mukherjee; Stephen B Gruber; Barbara J McKenna; Henry D Appelman; Joel K Greenson Journal: Am J Surg Pathol Date: 2008-11 Impact factor: 6.394